852814-99-4

Upstream product

• 645-13-6 4-isopropylacetophenone 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 852815-00-0 ethyl 1-methyl-3-[4-(1-methylethyl)phenyl]-1H-pyrazole-5-carboxylate 
• 852815-02-2 ethyl 1-methyl-5-[4-(1-methylethyl)phenyl]-1H-pyrazole-3-carboxylate 
• 1384878-30-1 1-[(2,4-dimethoxyphenyl)methyl]-3-hydroxy-4-{[4-(propan-2-yl)phenyl]carbonyl}-5-[4-(trifluoromethoxy)phenyl]-2,5-dihydro-1H-pyrrol-2-one 
• 1260598-07-9 1-(6-chloro-pyridazin-3-yl)-3-hydroxy-4-(4-isopropyl-benzoyl)-5-(4-trifluoromethoxy-phenyl)-1,5-dihydro-pyrrol-2-one 
• 1260597-59-8 3-hydroxy-4-(4-isopropyl-benzoyl)-1-(6-methyl-pyridazin-3-yl)-5-(4-trifluoromethoxy-phenyl)-1,5-dihydro-pyrrol-2-one 
• 1384878-08-3 3-hydroxy-1-(2-methylpyrimidin-5-yl)-4-{[4-(propan-2-yl)phenyl]carbonyl}-5-[4-(trifluoromethoxy)phenyl]-2,5-dihydro-1H-pyrrol-2-one 
• 1384878-09-4 3-hydroxy-1-(3-methyl-1,2,4-triazin-6-yl)-4-{[4-(propan-2-yl)phenyl]carbonyl}-5-[4-(trifluoromethoxy)phenyl]-2,5-dihydro-1H-pyrrol-2-one 
• 1384878-10-7 4-hydroxy-3-(4-isopropylbenzoyl)-1-(6-methyl-1,2,4-triazin-3-yl)-2-[4-(trifluoromethoxy)phenyl]-2H-pyrrol-5-one 
• 1384878-21-0 1-[6-(2-ethoxyethyl)pyridazin-3-yl]-3-hydroxy-4-{[4-(propan-2-yl)phenyl]carbonyl}-5-[4-(trifluoromethoxy)phenyl]-2,5-dihydro-1H-pyrrol-2-one 
• 1384878-02-7 3-hydroxy-4-(4-isopropylbenzoyl)-1-(6-methylpyridazin-3-yl)-5-(6-(trifluoromethoxy)pyridin-3-yl)-1H-pyrrol-2(5H)-one 
• 1384878-04-9 3-hydroxy-1-(6-isobutylpyridazin-3-yl)-4-(4-isopropylbenzoyl)-5-(4-(trifluoromethoxy)phenyl)-1H-pyrrol-2(5H)-one 
• 1384878-12-9 3-hydroxy-4-(4-isopropylbenzoyl)-1-(6-methylpyridazin-3-yl)-5(R)-(6-(trifluoromethoxy)pyridin-3-yl)-1H-pyrrol-2(5H)-one 
• 1384878-11-8 3-hydroxy-4-(4-isopropylbenzoyl)-1-(6-methylpyridazin-3-yl)-5(S)-(6-(trifluoromethoxy)pyridin-3-yl)-1H-pyrrol-2(5H)-one 
• 1384878-45-8 C₃₀H₃₁F₃N₄O₄ 

Relevant academic research and scientific papers

Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents

In our endeavour towards the development of effective anticancer therapeutics, a novel series of isoxazole-piperazine hybrids were synthesized and evaluated for their cytotoxic activities against human liver (Huh7 and Mahlavu) and breast (MCF-7) cancer ce

1-(6-MEMBERED AZO-HETEROCYCLIC)-2,5-DIHYDRO-1H-PYRROL-2-ONE DERIVATIVES AS ANTI-HEPATITIS C VIRUS, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE

The present invention concerns 1-(6-memberedazo-heterocyclic)-2,5-dihydro–1H–pyrrol–2-one compoundsof the following formula (I) or a salt, solvate, tautomer, isotope, enantiomer, diastereoisomer or racemic mixture thereof: the pharmaceutical composition thereof and their therapeutic use as inhibitors of Hepatitis C virus.

SUBSTITUTED PYRAZOLES AS PPAR AGONISTS

A compound of formula (I) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof (I) wherein: p is O or 1; q is O or 1; R1 and R2 are independently H or C1-3 alkyl; R3 and R4 are independently H, C1-6 alkyl, -OC1-6 alkyl, halogen, OH, C2-6 alkenyl or CF3; R5 is H, C1-6 alkyl (optionally substituted by one or more halogens, -COphenyl, OC1-6 alkyl, phenyl morpholino or C2-6 alkenyl. R6 is C1-6 alkyl, halogen, -OCH2 phenyl, phenyl (optionally substituted by C1-3 alkiyl), morpholino, pyrrolidino, piperidino, thiophenyl, furanyl pyridinyl or -OC2-6 alkenyl. These compounds activate the alpha and gamma subtypes fo the hppar receptor and are useful e.g. in the treatment of diabetes, dyslipidemia or syndrome X.